H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Rapt Therapeutics to $43 from $50 and keeps a Buy rating on the shares. The RPT193 Phase 2 top-line data is now slated for release in mid-2024 due to slow enrollment, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RAPT:
- Rapt Therapeutics Craters as Testing Proves a Challenge
- RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
- Rapt Therapeutics reports Q4 EPS (64c), consensus (66c)
- Rapt Therapeutics says $2M of cash held at Silicon Valley Bank
- RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
